- Home
- MODD vs LTRN Comparison
MODD vs LTRN Comparison
Compare MODD & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MODD | LTRN |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 22.2M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MODD | LTRN |
|---|---|---|
| Price | $4.16 | $3.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.9K | ★ 278.4K |
| Earning Date | 02-17-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.62 | 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $1.11 |
| 52 Week High | $6.16 | $5.74 |
Technical Indicators
Market Signals| Indicator | MODD | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 70.11 |
| Support Level | $0.41 | $3.09 |
| Resistance Level | $6.04 | $3.79 |
| Average True Range (ATR) | 0.44 | 0.30 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 75.62 | 88.28 |
Price Performance
Historical ComparisonAbout MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.